Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasm Metastasis 31Lung Neoplasms 25Carcinoma, Non-Small-Cell Lung 20Breast Neoplasms 19Lymphoma 18Multiple Myeloma 17Glioblastoma 17Prostatic Neoplasms 16Urinary Bladder Neoplasms 15Glioma 15Carcinoma, Renal Cell 15Melanoma 13Squamous Cell Carcinoma of Head and Neck 12Sarcoma 12Ovarian Neoplasms 12Colorectal Neoplasms 12Central Nervous System Neoplasms 12Triple Negative Breast Neoplasms 11Mouth Neoplasms 11Pancreatic Neoplasms 10Oropharyngeal Neoplasms 10Neuroblastoma 10Medulloblastoma 10Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Laryngeal Neoplasms 10Carcinoma, Transitional Cell 10Thyroid Neoplasms 9Fallopian Tube Neoplasms 9Ependymoma 9

Interventions

Melphalan 4sargramostim 3Peripheral Blood Stem Cell Transplantation 3Cyclophosphamide 3Interferon-alpha 2Filgrastim 2Dexamethasone 2Carboplatin 2Calcium Dobesilate 24'-deoxy-4'-iododoxorubicin 2venetoclax 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1X-Rays 1Sunitinib 1Specimen Handling 1Radiotherapy 1Pharmacogenomic Testing 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Ketamine 1Interleukin-12 Subunit p35 1Imatinib Mesylate 1Ifosfamide 1Docetaxel 1Decitabine 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Immunoglobulin Light-chain Amyloidosis × Magnetic Resonance Spectroscopy × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡